Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

miR-126 as a Therapeutic Agent for Diabetes Mellitus

Author(s): Elham Pishavar and Javad Behravan*

Volume 23, Issue 22, 2017

Page: [3309 - 3314] Pages: 6

DOI: 10.2174/1381612823666170424120121

Price: $65

Abstract

Diabetes mellitus (DM) is a metabolic disorder which is characterized by inappropriate hyperglycemia. It is becoming an epidemic disease in developing countries. Diabetic patients are frequently afflicted with a vascular dysfunction and wound healing defect. In spite of intense investigations, over the past 2-3 decades, optimal treatment options and related mechanisms are still unclear. MicroRNAs (miRNAs) are small noncoding RNAs considered as regulators of a vast number of biological processes including endothelial cell function controlling molecular signaling pathways in diabetic pathogenesis. Down regulation of microRNA-126 (miR-126) which may regulate angiogenesis and vascular integrity plays a significant role in the pathogenesis and complications of DM. This paper discusses the potential application of miR-126 as a novel therapeutic agent capable of reducing diabetic vascular complications in different types of DM based on the up-to-date reports.

Keywords: Angiogenesis, diabetes mellitus, miR-126, vascular complications, microRNAs, hyperglycemia.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy